nutrients-logo

Journal Browser

Journal Browser

Dietary Macronutrients and Cardiometabolic Diseases

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Clinical Nutrition".

Deadline for manuscript submissions: closed (25 February 2023) | Viewed by 3137

Special Issue Editor


E-Mail Website
Guest Editor
Cheeloo College of Medicine, Shandong University, Jinan, China
Interests: molecular nutrition; dietary supplements; cardiac rehabilitation strategy; natural product; sulforaphane; resveratrol

Special Issue Information

Dear Colleagues,

Cardiometabolic diseases continue to be the most important and leading causes of morbidity and mortality globally. Among cardiometabolic disorders, cardiovascular diseases (CVDs) have the greatest prevalence; other cardiometabolic disorders closely related to CVDs such as diabetes mellitus and obesity produce even larger global health burdens. The benefits of consuming a high-quality diet and the role of diet essential nutrition in safeguarding cardiometabolic disease have attracted a great deal of attention.

Recently, nutrition science has advanced remarkably. In comparison with historical dietary recommendations which were based largely on cross-national studies, short-term experiments, and animal models, nutrition science has been transformed in the past two decades by more rigorous evidence from well-designed metabolic studies, prospective cohorts, and randomized clinical trials. From this perspective, it may be required to accurately analyze effective dietary components or active ingredients and subsequently establish individually optimized prevention methods for cardiometabolic health in the future.

Therefore, this Special Issue titled “Dietary Macronutrients and Cardiometabolic Diseases” aims to elucidate the role of dietary essential nutrition, natural products, diet active ingredients, or specific foods that influence cardiometabolic disorder in the context of increased adiposity or diabetes. Articles that shed light on how these factors control the development and progressions of cardiometabolic disorder, which ultimately characterize and implement evidence-based strategies for lifestyle change, are invited. More importantly, comprehensively regulatory mechanisms of dietary nutrients in cardiometabolic diseases are particularly welcome.

Prof. Dr. Junlian Gu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diet supplements
  • essencial nutrients
  • cardiometabolic disease
  • micronutrients
  • obesity
  • diabetes

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 4714 KiB  
Article
Resveratrol and FGF1 Synergistically Ameliorates Doxorubicin-Induced Cardiotoxicity via Activation of SIRT1-NRF2 Pathway
by Guangping Lu, Qingbo Liu, Ting Gao, Jiahao Li, Jingjing Zhang, Ou Chen, Cong Cao, Min Mao, Mengjie Xiao, Xiaohui Zhang, Jie Wang, Yuanfang Guo, Yufeng Tang and Junlian Gu
Nutrients 2022, 14(19), 4017; https://doi.org/10.3390/nu14194017 - 27 Sep 2022
Cited by 12 | Viewed by 2832
Abstract
Doxorubicin (DOX) has received attention due to dose-dependent cardiotoxicity through abnormal redox cycling. Native fibroblast growth factor 1 (FGF1) is known for its anti-oxidative benefits in cardiovascular diseases, but possesses a potential tumorigenic risk. Coincidentally, the anti-proliferative properties of resveratrol (RES) have attracted [...] Read more.
Doxorubicin (DOX) has received attention due to dose-dependent cardiotoxicity through abnormal redox cycling. Native fibroblast growth factor 1 (FGF1) is known for its anti-oxidative benefits in cardiovascular diseases, but possesses a potential tumorigenic risk. Coincidentally, the anti-proliferative properties of resveratrol (RES) have attracted attention as alternatives or auxiliary therapy when combined with other chemotherapeutic drugs. Therefore, the purpose of this study is to explore the therapeutic potential and underlying mechanisms of co-treatment of RES and FGF1 in a DOX-treated model. Here, various cancer cells were applied to determine whether RES could antagonize the oncogenesis effect of FGF1. In addition, C57BL/6J mice and H9c2 cells were used to testify the therapeutic potential of a co-treatment of RES and FGF1 against DOX-induced cardiotoxicity. We found RES could reduce the growth-promoting activity of FGF1. Additionally, the co-treatment of RES and FGF1 exhibits a more powerful cardio-antioxidative capacity in a DOX-treated model. The inhibition of SIRT1/NRF2 abolished RES in combination with FGF1 on cardioprotective action. Further mechanism analysis demonstrated that SIRT1 and NRF2 might form a positive feedback loop to perform the protective effect on DOX-induced cardiotoxicity. These favorable anti-oxidative activities and reduced proliferative properties of the co-treatment of RES and FGF1 provided a promising therapy for anthracycline cardiotoxicity during chemotherapy. Full article
(This article belongs to the Special Issue Dietary Macronutrients and Cardiometabolic Diseases)
Show Figures

Graphical abstract

Back to TopTop